Clinical trial
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
NCT02246127 is registered in ClinicalTrials.gov with Grupo Espanol de Tumores Neuroendocrinos as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
- Lead sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 27, 2014
- Completion date
- July 12, 2021
- Enrollment
- 141 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.